A Study of GLWL-01 in Patients With Prader-Willi Syndrome

PHASE2CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

February 20, 2018

Primary Completion Date

June 12, 2019

Study Completion Date

June 12, 2019

Conditions
Prader-Willi Syndrome
Interventions
DRUG

GLWL-01

Oral administration of 3 capsules, twice a day

DRUG

Placebo

Oral administration of 3 capsules, twice a day

Trial Locations (7)

32601

University of Florida, Gainesville

37232

Vanderbilt University, Nashville

44106

University Hospitals, Cleveland Medical Center, Cleveland

92123

Rady Children's Hospital San Diego, San Diego

T6G 2B7

Alberta Diabetes Institute, University of Alberta, Edmonton

H2W 1T8

CRCHUM, Montreal

H3T 1C5

Centre Hospitalier Universitaire Ste-Justine, Montreal

Sponsors

Lead Sponsor

All Listed Sponsors
lead

GLWL Research Inc.

OTHER

NCT03274856 - A Study of GLWL-01 in Patients With Prader-Willi Syndrome | Biotech Hunter | Biotech Hunter